Screener
Kyverna Therapeutics, Inc. KYTX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026. Open the filing →
- Filed
- May 12, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219397
FAQ
- What is Kyverna Therapeutics, Inc.'s EPS (diluted)?
- Kyverna Therapeutics, Inc. (KYTX) reported EPS (diluted) of -$0.66 in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
- Kyverna Therapeutics, Inc.'s EPS (diluted) increased by 35.9% year-over-year, from -$1.03 to -$0.66.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s EPS (diluted)?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s EPS (diluted) has grown at a -79.1% compound annual growth rate (CAGR), from -$83.09 to -$3.64.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Kyverna Therapeutics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude